SIRT1 is essential for oncogenic signaling by estrogen/ estrogen receptor α in breast cancer

Cancer Research

Volumn 71, Issue 21, 2011, Pages 6654-6664

  Elangovan, Selvakumar ^a   Ramachandran, Sabarish ^a   Venkatesan, Narayanan ^b   Ananth, Sudha ^a   Gnana Prakasam, Jaya P ^a   Martin, Pamela M ^a   Browning, Darren D ^a   Schoenlein, Patricia V ^a   Prasad, Puttur D ^a   Ganapathy, Vadivel ^a   Thangaraju, Muthusamy ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CATALASE; CYCLIN G2; ESTROGEN; ESTROGEN RECEPTOR ALPHA; GLUTATHIONE PEROXIDASE; PROTEIN P53; SIRTUIN 1;

APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CELL GROWTH; GENE ACTIVATION; GENE INACTIVATION; GENETIC TRANSCRIPTION; HUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN INTERACTION; RECEPTOR BINDING; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

ACETYLATION; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; BREAST NEOPLASMS; CELLS, CULTURED; EPITHELIAL CELLS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR MODULATORS; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTATHIONE PEROXIDASE; HUMANS; LIPID PEROXIDATION; MICE; MICE, NUDE; NEOPLASM PROTEINS; NEOPLASMS, HORMONE-DEPENDENT; PROTEIN INTERACTION MAPPING; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIGNAL TRANSDUCTION; SIRTUIN 1; SPECIFIC PATHOGEN-FREE ORGANISMS; SUPEROXIDE DISMUTASE; TUMOR STEM CELL ASSAY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80155126751     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-1446     Document Type: Article

References (36)

1. Dali-Youcef N, Lagouge M, Froelich S, Koehl C, Schoonjans K, Auwerx J. Sirtuins: the 'magnificient seven', function, metabolism and longevity. Ann Med 2007;39:335-45.
2. Haigis MC, Guarente LP. Mammalian sirtuins-emerging roles in physiology, aging, and calorie restriction. Genes Dev 2006;20:2913-21. (Pubitemid 44771725)
3. Feige JN, Auwerx J. Transcriptional targets of sirtuins in the coordination of mammalian physiology. Curr Opin Cell Biol 2008;20: 303-9.
4. Michan S, Sinclair D. Sirtuins in mammals: insights into their biological function. Biochem J 2007;404:1-13. (Pubitemid 46788079)
5. Huffman DM, Grizzle WE,BammanMM, Kim JS, Eltoum IA, Elgavish A, et al. SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res 2007;67:6612-8. (Pubitemid 47105506)
6. Kim JE, Chen J, Lou Z. DBC1 is negative regulator of SIRT1. Nature 2008;451:583-6.
7. Chen WY, Wang DH, Yen RC, Luo J, Gu W, Baylin SB. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell 2005;123:437-48. (Pubitemid 41546674)
8. Brooks CL, Gu W. How does SIRT1 affect metabolism, senescence and cancer? Nat Rev Cancer 2009;9:123-8.
9. Campisi J. Suppressing cancer: the importance of being senescent. Science 2005;309:886-7. (Pubitemid 41099913)
10. Ota H, Tokunage E, Chang K, Hikasa M, Lijima K, Eto M, et al. Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MPAK signaling in human cancer cells. Oncogene 2006;25:176-85. (Pubitemid 43083679)
11. Vaziri H, Dessain SK, Ng Eaton E, Imai S, Frye RA, Pandita TK, et al. hSIR2 (SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001;107:149-59. (Pubitemid 33035942)
12. Yamakuchi M, Ferlito M, Lowenstein CJ. miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci USA 2008;105:13421-6.
13. Nemoto S, Fergusson MM, Finkel T. Nutrient availability regulates SIRT1 through a forkhead dependent pathway. Science 2004;306: 2105-8. (Pubitemid 40007664)
14. Firestein R, Blander G, Michan S, Oberdoerffer P, Ogino S, Campbell J, et al. The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One 2008;3:e2020.
15. Wang R, Zhang, Kim HS, Xu X, Cao L, Luhasen T, et al. Interplay among BRCA1, SIRT1, and survivin during BRCA1-associated tumorigenesis. Mol Cell 2008;32:11-20.
16. Deroo BJ, Korach KS. Estrogen receptors and human diseases. J Clini Invest 2006;116:561-70.
17. Clarke RB, Anderson E, Howell A. Steroid receptors in human breast cancer. Trends Endocrinol Metab 2004;15:316-23. (Pubitemid 39180006)
18. Holst F, Stahl PR, Ruiz C, Hellwinkel O, Jehan Z, Wendland M, et al. Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat Genet 2007;39:655-60. (Pubitemid 46676104)
19. Cooper JA, Rohan TE, Cant EL, Horsfall DJ, Tilley WD. Risk factors for breast cancer by oestrogen receptor status: a population-based casecontrol study. Br J Cancer 1989;59:119-25.
20. Kazi AA, Jones JM, Koos RD. Chromatin immunoprecipitation analysis of gene expression in the rat uterus in vivo: Estrogen-induced recruitment of both estrogen receptora and hypoxia-inducible factor 1 to the vascular endothelial growth factor promoter. Mol Endocrinol 2005;19: 2006-19. (Pubitemid 41130691)
21. Kim MY, Woo EM, Chong YT, Homenko DR, Kraus WL. Acetylation of estrogen receptor a by p300 at lysine 266 and 268 enhances the deoxyribonucleic acid binding and transactivation activities of the receptor. Mol Endocrinol 2006;20:1479-93. (Pubitemid 43967558)
22. Yao Y, Li H, Gu Y, Davidson NE, Zhou Q. Inhibition of SIRT1 deacetylase suppresses estrogen receptor signaling. Carcinogenesis 2010;31:382-7.
23. Li H, Rajendran GK, Liu N, Ware C, Rubin BO, Gu Y. SirT1 modulates the estrogen-insulin-like growth factor-1 signaling for postnatal development of mammary gland in mice. Breast Cancer Res 2007;9:R1-12.
24. Elpaz A, Rivas D, Duque G. Effect of estrogens on bone marrow adipogenesis and Sirt1 in aging C57BL/6J mice. Biogerontol 2009;10:744-55.
25. Yao Y, Brodie AMH, Davidson NE, Kensler TW, Zhou Q. Inhibition of estrogen signaling activates the NRF2 pathway in breast cancer. Breast Cancer Res Treat 2010;124:585-91
26. Laudet V, Hanni C, Coll J, Catzeflis F, Stehelin D. Evolution of the nuclear receptor gene super family. EMBO J 1992;11:1003-13.
27. Stein RA, McDonnell DP. Estrogen-related receptor alpha as a therapeutic target in cancer. Endocr Relat Cancer 2006;13 Suppl. 1: S25-32. (Pubitemid 46219246)
28. Vina J, Consuelo BS, Gambini J, Sastre J, Pallardo FV. Why females live longer than males? Importance of the upregulation of longevityassociated genes by oestrogenic compounds. FEBS Letts 2005;579: 2541-5. (Pubitemid 40626754)
29. Dioum EM, Chen R, Alexander MS, Zhang Q, Hogg RT, Gerard RD, et al. Regulation of hypoxia-inducible factor 2alpha signaling by the stress-responsive deacetylase sirtuin 1. Science 2009;324: 1289-93.
30. Liu W, Konduri SD, Bansal S, Nayak BK, Rajasekaran SZ, Karuppayil SM, et al. Estrogen receptor-a binds p53 tumor suppressor protein directly and represses the function. J Biol Chem 2006;281: 9837-40. (Pubitemid 43864514)
31. Perissi V, Jepsen K, Glass CK, Rosenfeld MG. Deconstructing repression: Evolving models of co-repressor action. Nat Rev Genet 2010;11: 109-23.
32. Stein RA, Chang CY, Kazmin DA, Way J, Schroeder T, Wergin M, et al. Estrogen-related receptor alpha is critical for the growth of estrogen receptor-negative breast cancer. Cancer Res 2008;68:8805-12.
33. Wilson BJ, Tremblay AM, Deblois G, Sylvain-Drolet G, Giguère V. An acetylation switch modulates the transcriptional activity of estrogenrelated receptor alpha. Mol Endocrinol 2010;24:1349-58.
34. Stossi F, Likhite VS, Katzenellenbogen JA, Katzenellenbogen BS. Estrogen-occupied estrogen receptor represses cyclin G2 gene expression and recruits a repressor complex at the cyclin G2promoter. J Biol Chem 2006;281:16271-8.
35. Cheng HL, Mostolavsky R, Saito S, Manis JP, Gu Y, Patel P, et al. Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc Natl Acad Sci U S A 2003;100: 10794-9. (Pubitemid 37140107)
36. Zhao W, Kruse JP, Tang Y, Jung SY, Qin J, Gu W. Negative regulation of the deacetylase SIRT1 by DBC1. Nature 2008;451:587-90. (Pubitemid 351186268)